Instructions:

- 1. Please type all information and complete all applicable sections. You may add additional lines if needed.
- 2. List all supporting documents in Appendix 3 under the pertinent section(s) of the ABAT Credentialing Application.
- 3. Completed and signed applications should be submitted to the Chair of ABAT's Credentialing Committee at ABATCredentialing@clintox.org.
- 4. Due Dates:

A completed electronic version (PDF) of this document is due by July 1 for applicants completing a clinical toxicology training program under the direction of a DABAT or FAACT.

A completed electronic version (PDF) of this document is due by March 1 for all other interested applicants.

5. Fees:

Application Fee of \$200 and Examination Fee of \$300 must be received within 10 days of receipt of application.

Contact the Chair of ABAT's Credentialing Committee at ABATCredentialing@clintox.org for payment and mailing instructions.

Payment must be submitted in two separate checks made payable to "American Board of Applied Toxicology". If credentialing is denied for any reason, the \$300 examination fee will be refunded.

Applicant's Contact Information	
) certify that the information d any and all supporting material submitted is accurate and eleted as listed.
Applicant Signature	Date
	st-Graduate Training Program Directors
) certify that the information s accurate and all items have been completed as listed.
Residency/Fellowship Direct	for Signature Date

1. Education and Licensure				
Graduate of an accredited college or university with at least a bachelor's degree in a biomedical discipline Degree(s):				
University(ies): Graduation Date(s):	ABAT Reviewer:			
Applicant is a healthcare professional and holds a valid, unrestricted license to practice Profession: License Number: State: Expiration Date:	in the United States			
Applicants without a requirement for licensure are exempt from this criterion. Please provide explanation if not required to cold a current license to practice: ABAT Reviewer: Yes No				
O Tayloology Experience				

2. Toxicology Experience

Applicants holding a master's or doctoral degree are required to have a minimum of 2 years of full-time experience in clinical toxicology or an equivalent part-time experience.

Applicants with a bachelor's degree in a biomedical discipline must have a minimum of 5 years of full-time experience in clinical toxicology or an equivalent part time experience

The experiential requirement could be satisfied through one of the following post-graduate training program options:

 Completion of a formal, full-time 24-month training program in clinical toxicology under the direction of a DABAT or AACT fellow.

OR

 Completion of a formal, full-time 12-month training program in clinical toxicology under the direction of a DABAT or AACT fellow preceded by a 1-year formal training program in a related healthcare field (e.g. PGY1 pharmacy residency)

OR

• Completion of an ASHP accredited PGY2 Emergency Medicine pharmacy residency plus the equivalent of 1 year of full-time experience in clinical toxicology

OR

• Completion of an ASHP accredited PGY2 pharmacy residency other than Emergency Medicine plus the equivalent of 1.5 years of full-time experience in clinical toxicology

Equivalent part time experience

- 1 year full-time = 2 years at 50% time = 4 years at 25%. Time is based on an average 40-hour work week
- Candidates submitting poison information specialist work as part of their application must be certified by the AAPCC for a minimum of 3 years
- · Scholastic coursework is not considered to be professional experience

Post-Graduate Training			
	Institution & Location	Program Director	Dates
24-Month Clin. Tox. Fellowship			

ASHP Accree Pharmacy Re	esidency					
ASHP Accree Pharmacy Re Specialty:						
		Toxicology-Rela	ated Employment			
Position	Emplo (Institution/Facility/Dep		Tox-Related Responsibilitie	s hrs	erage /week n Tox	Employment Dates
ED Clinical Pharmacist	University Medical Cent	er; Anytown, State	Provide a description of y related responsibilities, ac clinical and teaching invol	ctivities,	8	Aug 2012 - current
50 direct hede	ide tovicology natient con		on Requirements		Yes	S No
OR 35 or more dire	ide toxicology patient con ect, bedside patient consu hone/telemedicine consul	Itations + enough te			o equal	50
·	te Appendix 1 and, if nece			care cirrician		
		Number of Cons	ultations Completed	ſ	Date Ra	nge
Direct, Be	dside Patient Consults					
	Telemedicine Consults					
Telephone/						
Telephone/	Total #					
Graduates of Co	Total # Clinical Toxicology Fellows pendix 1 and 2, but progr ing Committee reserves to	am director should	keep log on file as proo	f of completion	n of this	requirement.

4. Didactic Teaching/Preceptorship

Provide evidence of a minimum of 5 presentations in clinical toxicology to learners (students or residents) for a cumulative total of at least 5 hours.

Teaching could be provided to rotators on clinical rotations, as an academic course in clinical toxicology, **OR** as grand rounds seminars.

Didactic Teaching

	Lecture Title	Location	Length (hr)	Learners (Type & # attended)	Dates
	Over-the-Counter & Over the Edge – APAP, Salicylate, & NSAID Toxicities	State University College of Medicine	1 hour	80 3 rd year medical students per year	Presented monthly during EM rotation 2016 - current
1					
2					
3					
4					
5					
6					

Please list any precepting experience (providing clinical education and overseeing care provided by) of patient care clinical learners in clinical toxicology.

Preceptorship

	Institution (University & Program)	Rotation Title	Rotation Description	Dates		
	State University College of Nursing	Poison Center/Toxicology	Community Health elective for nursing students in last semester of BSN program	2015 – 2019 academic years		
1						
2						
3						
4						

3		
4		
		ABAT Reviewer: Yes No

5. Research Protocols

Provide evidence of designing and conducting at least one research study in clinical toxicology. (This can include related studies such as surveillance of adverse drug events, drug interactions, etc., quality assurance activities regarding the assessment and treatment of poisoned patients, or medication use evaluations related to clinical toxicology.)

	Study Title	Role (i.e. PI, Coordinator, etc.)	Brief Description of Study	IRB Approved (Y/N)	Dates
	Please Pick Your Poison	Principal Investigator	Prospective descriptive review of suspected human exposures to	Y	6/21/19 - ongoing
1					
2					

ABAT Reviewer:		
Yes	No	

6. Research Publications

Provide evidence of authoring at least one peer-reviewed publication related to research (case series or research study) in clinical toxicology (or related topic such as adverse drug events, drug interactions, etc.).

	Citation in APA Format			
	(https://apastyle.apa.org/)			
	Garrard A, Sollee DR, Butterfield RC, Johannsen L, Wood A, Bertholf RL. Validation of a pre-existing formula to calculate the contribution of			
4	ethanol to the osmolar gap. Clin Toxicol (Phila). 2012;50(7):562-566. doi:10.3109/15563650.2012.704039			
•				
2				
3				

ABAT Reviewer:		
Yes	☐ No	

7. Non-Research Publications

Provide evidence of having authored at least 2 publications related to clinical toxicology that are not the result of research conducted by the applicant (e.g. book chapters, review articles, case reports, etc.).

- Four newsletter articles (or equivalent, i.e. blogs) = 1 publication.
- Newsletter articles may only be used to satisfy one of the two required publications; the other needs to be a peer-reviewed submission.

		Citation	Publication Type
		"Chloroquine and Hydroxychloroquine: Old Drugs, Still Just as Toxic" in March 2020's ToxTidbits from the Maryland Poison Center	Newsletter
		Meier, Kathryn H, Rodenticides, Miscellaneous, in <u>Poisoning and Drug Overdose</u> , 7 th edition in Olson KR et al, eds. McGraw-Hill Companies Inc. New York NY, 5 th edition. New York, NY. 2018	Peer-reviewed Book Chapter/Monograph
1			
2	- 2		
3			
4	ļ		

$\frac{1}{2}$	ABAT R	eviewer:
	Yes	No

8. Professional Presentations

Provide evidence of having given at least 4 presentations on clinical toxicology to other professionals (e.g. poster presentation, continuing education programs, platform presentation, grand rounds seminar, webinars, etc.)

	Title	Presentation Type	Description (& CME, CNE, or ACPE applicable)		Date
	Toxic Jeopardy	Live CE presentation	Presented at 6 th Annual Pills & Kill! – Toxicology in Review in for CME, CNE, & ACPE UAN # 19-090-L01-P	El Paso, TX	3/28/2019
1					
2					
3					
4					
5					
				ABAT Revi	ewer:

9. Editorial/Reviewer Duties

Serve as an editor, editorial board member, or peer reviewer for health care or toxicology-related publication/journal OR

Peer reviewer for abstracts submitted to a toxicology-related conference

Other editorial/reviewer activity will be considered based on information provided by the candidate (e.g. expert witness work, Pharmacy & Therapeutics Committees, monographs for drug databases, etc.). More complete descriptions and supporting documents may be referenced here and added in Appendix 3.

	Journal or Conference*	Total Peer Reviews	Date Range
Conference Abstract	TSHP Alcalde Southwest Leadership Conference	80	2015-2019
Peer Reviewer	2. Pills & Thrills that Kill - Toxicology in Review	10	2018-2020
Editor			
Editorial Board			
Member			
Journal Peer Reviewer			
Conference			
Abstract Peer			
Reviewer			

^{*}You may enter more than one journal or conference per type of editor/reviewer category. Be sure to provide complete information for each entry.

Expert Witness	Brief Description of Case & Your Involvement	Date

Pharmacy & Therapeutics Committee	(inclu	Brief Description of Involvement in P&T de any MUE or drug class monographs you prepared)	Date
Drug Monographs for Databases	Database	Brief Description	Date
Describe other act	ivities below:		
		ABAT Revie	ewer:
Local examActive servi	ples include emerge	10. Committee Work one toxicology related committee (e.g. local, regional, or national). ency preparedness, pharmacy safety and therapeutics, quality and safety leadership position within the committee or providing objective evidence.	

	Committee	Organization	Role & Responsibilities	Date Range
	SPI Committee	AAPCC	NACCT Planning Sub-committee Chair – responsible for identifying topics and speakers then obtaining the required documents for CE approvals for NACCT SPI Symposium	2015-2018
1				
2				
3				

ABAT R	eviewer:
Yes	No

11. Community Education

Provide evidence of a minimum of 5 presentations (or other educational activity including media appearances) to the lay public on topics related to clinical toxicology.

	Topic/ Presentation	Audience	Brief Description	Date
	Safe Cleaning Practices during COVID-19	General TV audience	Interview by KVIA-7 regarding exposure risks from cleaning products and poison prevention tips during COVID-19 pandemic	05/08/20
1				
2				

3			
4			
5			
		ABAT Rev	iewer:
			_

Reference #1 Information	
Name:	
Email:	
Phone:	
Mailing Address:	
Reference #2 Information	
Name:	
Email:	
Phone:	
Mailing Address:	
Reference #3 Information	
Name:	
Email:	
Phone:	
Mailing Address:	

Appendix 1. Direct, Bedside Patient Consults

	Appendix 1. Direct, Bedside Patient Consults					
	Date (M/Yr)	Consult Requested By:	Title or Topic	Scenario	Recommendation / Monitoring	Follow-Up
	05/19	ED MD	APAP ER	15 y F ingested handful of 650mg Tylenol 10hrs prior to arrival	Start IV NAC, trend APAP q4h x3, continue NAC if any APAP crosses nomogram line	Rec repeat NAC bag #3 due to lingering APAP levels after 21hr NAC. Discharged on HD3.
1						
3						
4						
5						
6						
7						
8						
9						
10						
12						
13						
14						
15						
16						
17 18						
19						
20						
21						
22						
23						
24						
25 26						
27						
28						
29						
30						
31						
32 33						
34						
35						
36						
37						
38						
39						
40						
42						
43						
44						
45						
46						
47 48						
48						
50						
			1	i	1	ı

Appendix 2. Telephone/Telemedicine Consults

	Appendix 2. Telephone/Telemedicine Consults					
	Date (M/Yr)	Consult Requested By:	Title or Topic	Scenario	Recommendation / Monitoring	Follow-Up
1	06/19	ICU Medical Team	Chronic digoxin	68 Y F with multiple myeloma & A Fib on dig, presents to ED with UTI, SCr=4, hypotension and bradycardia, digoxin=4.0. K 5.8	Unclear home dig dosing. Repeat dig level now. Give first vial of Digoxin Fab, more Fab pending result.	Patient recovered after 4 day hospitalization
2						
3						
4						
5						
6						
7						
8						
9						
10						
11						
12						
13						
14						
15						
16						
17						
18						
19						
20						
21						
22						
23						
24						
25						
26						
27 28						
29						
30						
31						
32						
33						
34						
35						
36						
37						
38				_		
39						
40						
41		<u> </u>				
42						
43						
44 45						
45						

Appendix 3. Supporting Documents

Please list supporting documents included as attachments to any and all of the credentialing requirements:

1. Education and Licensure

2.	Toxicology Experience
3.	Consultations
4.	Didactic Teaching/Preceptorship
5.	Research Protocols
6.	Research Publications
7.	Non-Research Publications
8.	Professional Presentations
9.	Editorial/Review Duties
10.	. Committee Work
11.	. Community Education